PDF herunterladen
Dtsch Med Wochenschr 2014; 139(06): 234-236
DOI: 10.1055/s-0033-1360060
Endokrinologie & Diabetologie | Commentary
Diabetologie
© Georg Thieme Verlag KG Stuttgart · New York

Personalisierte Medizin und Typ-2-Diabetes: Pharmakogenetische Aspekte bei der Therapie

Personalized medicine and type-2 diabetes: pharmakogenetic aspects of drug therapy
A. Barthel
1   Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
5   Endokrinologikum Ruhr, Bochum
,
P. Schwarz
1   Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
,
C. Schindler
2   Klinisches Forschungszentrum – CRC Hannover, Medizinische Hochschule Hannover
,
S. R. Bornstein
1   Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
3   Paul-Langerhans-Institut für Diabetesforschung, Technische Universität Dresden
4   Center of Regenerative Therapies, Dresden
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. Januar 2014 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Schlüsselwörter

Typ-2-Diabetes - Arzneimitteltherapie - Pharmakogenetik - personalisierte Medizin

Keywords

diabetes mellitus type 2 - drug therapy - pharmacogenetics - personalized medicine
 

  • Literatur

  • 1 Chen S, Zhou J, Xi M et al. Pharmacogenetic variation and metformin response. Curr Drug Metab 2013; 14: 1070-1082
    CrossrefPubMedGoogle Scholar
  • 2 Floegel A, Stefan N, Yu Z et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013; 62: 639-648
    CrossrefPubMedGoogle Scholar
  • 3 Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol 2012; 30: 1117-1124
    CrossrefPubMedGoogle Scholar
  • 4 Kwak SH, Park KS. Genetics of type 2 diabetes and potential clinical implications. Arch Pharm Res 2013; 36: 167-177
    CrossrefPubMedGoogle Scholar
  • 5 Mannino GC, Sesti G. Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data. Mol Diagn Ther 2012; 16: 285-302
    CrossrefPubMedGoogle Scholar
  • 6 Morris AP, Voight BF, Teslovich TM et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012; 44: 981-990
    CrossrefPubMedGoogle Scholar
  • 7 Sanghera DK, Blackett PR. Type 2 Diabetes Genetics: Beyond GWAS. J Diabetes Metab 2012; 3, pii: 6948
    PubMedGoogle Scholar
  • 8 Schindler C, Barthel A, Fischer S et al. Nutzen und Risiken der modernen Pharmakotherapie des Typ-2-Diabetes. Internist 2012; 53: 478, 480-485, 487
    PubMedGoogle Scholar
  • 9 Scott RA, Lagou V, Welch RP et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 2012; 44: 991-1005
    CrossrefPubMedGoogle Scholar
  • 10 Seeringer A, Parmar S, Fischer A et al. Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabetics. Diabetes Obes Metab 2010; 12: 1106-1112
    CrossrefPubMedGoogle Scholar
  • 11 van Leeuwen N, Nijpels G, Becker ML. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes. Diabetologia 2012; 55: 1971-1977
    CrossrefPubMedGoogle Scholar
  • 12 van Leeuwen N, Swen JJ, Guchelaar HJ et al. The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs. Clin Pharmacokinet 2013; 52: 833-854
    CrossrefPubMedGoogle Scholar
  • 13 Waldeyer R, Brinks R, Rathmann W et al. Projection of the burden of type 2 diabetes mellitus in Germany. Diabet Med 2013; 30: 999-1008
    CrossrefPubMedGoogle Scholar
  • 14 Wang-Sattler R, Yu Z, Herder C et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012; 8: 615
    PubMedGoogle Scholar
  • 15 Zhou K, Bellenguez C, Spencer CC et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011; 43: 117-120
    CrossrefPubMedGoogle Scholar